Imatinib Mesylate (CAS 220127-57-1) Suppliers and Product Information

Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. It is a potent inhibitor of the Bcr-Abl kinase, as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. It is used for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), and acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome.

Frequently Asked Questions about Imatinib Mesylate

Q: What is the primary use of Imatinib mesylate?

A: Imatinib mesylate is primarily used for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST) that express Kit, and acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome.

Q: How does Imatinib mesylate work?

A: Imatinib mesylate works as a tyrosine kinase inhibitor. It inhibits the Bcr-Abl kinase, which is encoded by the bcr-abl oncogene, as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. This inhibition decreases proliferation and enhances apoptosis in leukemia cells.

Q: What are the common side effects of Imatinib mesylate?

A: Common side effects include nausea, vomiting, heartburn, and headache. More severe side effects can include ascites, neutropenia, thrombocytopenia, skin rash, and pulmonary edema. However, it is generally better tolerated than many other medications used in treating the same diseases.

Q: How is Imatinib mesylate administered?

A: Imatinib mesylate is available in 100 and 400 mg capsules for oral administration. The bioavailability of the agent is nearly 100% by the oral route.